These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Vascular effects of calcium channel antagonists: new evidence. Richard S Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057 [TBL] [Abstract][Full Text] [Related]
5. [Calcium antagonists: current and future applications based on new evidence. Cardio-protective effect of calcium antagonists]. Hongo K; Yoshimura M Clin Calcium; 2010 Jan; 20(1):89-93. PubMed ID: 20048439 [TBL] [Abstract][Full Text] [Related]
6. [Calcium channel blockers in the treatment of cardiovascular disease]. Halawa B Pol Merkur Lekarski; 2001 Jul; 11(61):83-7. PubMed ID: 11579840 [TBL] [Abstract][Full Text] [Related]
7. Excitation-contraction coupling in cardiac and vascular smooth muscle: modification by calcium-entry blockade. McCall D Circulation; 1987 Jun; 75(6 Pt 2):V3-14. PubMed ID: 2436829 [TBL] [Abstract][Full Text] [Related]
8. [Differential therapy with calcium antagonists]. Scholze JE Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111 [TBL] [Abstract][Full Text] [Related]
9. Comparative clinical pharmacology of calcium channel blockers. Kim KE Am Fam Physician; 1991 Feb; 43(2):583-8. PubMed ID: 1990741 [TBL] [Abstract][Full Text] [Related]
10. [Calcium inhibitors and myocardial ischemia]. Thuillez C Therapie; 1993; 48 Spec No():671-6. PubMed ID: 8091353 [TBL] [Abstract][Full Text] [Related]
11. [Calcium antagonists and ischemic heart disease]. Simon K; Vályi P; Szépvölgyi A; Badics A; Böhm T Orv Hetil; 1996 Sep; 137(39):2131-6. PubMed ID: 8927361 [TBL] [Abstract][Full Text] [Related]
12. [Role of calcium antagonists in the treatment of arterial hypertension]. Velasco M; Negrín C Invest Clin; 1997 Nov; 38 Suppl 2():65-72. PubMed ID: 9471233 [TBL] [Abstract][Full Text] [Related]
13. Calcium-channel blockers for combined systemic hypertension and myocardial ischemia. Frishman WH; Charlap S Circulation; 1987 Jun; 75(6 Pt 2):V154-62. PubMed ID: 3552312 [TBL] [Abstract][Full Text] [Related]
14. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Opie LH; Yusuf S; Kübler W Prog Cardiovasc Dis; 2000; 43(2):171-96. PubMed ID: 11014332 [TBL] [Abstract][Full Text] [Related]
15. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Tomassoni D; Lanari A; Silvestrelli G; Traini E; Amenta F Clin Exp Hypertens; 2008 Nov; 30(8):744-66. PubMed ID: 19021025 [TBL] [Abstract][Full Text] [Related]
16. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. Morimoto S; Yano Y; Maki K; Iwasaka T J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563 [TBL] [Abstract][Full Text] [Related]
17. Acute hypertension and calcium-channel blockers. Kanneganti M; Halpern NA New Horiz; 1996 Feb; 4(1):19-25. PubMed ID: 8689271 [TBL] [Abstract][Full Text] [Related]
18. The voltage-dependent non-selective cation channel sensitive to the L-type calcium channel blocker efonidipine regulates Ca2+ influx in brain vascular smooth muscle cells. Matsuoka T; Nishizaki T; Nomura T Biochem Biophys Res Commun; 1997 Nov; 240(2):484-7. PubMed ID: 9388505 [TBL] [Abstract][Full Text] [Related]
19. [Mechanism of action of calcium antagonists in the treatment of vascular diseases]. Mayerhofer S Wien Med Wochenschr; 1986 Nov; 136(21-22):591-4. PubMed ID: 2435066 [TBL] [Abstract][Full Text] [Related]